FEMY
Femasys Inc
$
0.657
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.8793
Open
0.8054
VWAP
0.75
Vol
91.96M
Mkt Cap
28.26M
Low
0.620
Amount
69.29M
EV/EBITDA(TTM)
--
Total Shares
22.22M
EV
30.26M
EV/OCF(TTM)
--
P/S(TTM)
8.37
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
1.27M
+128.27%
-0.117
-51.39%
1.65M
+183.71%
-0.083
-63.77%
2.07M
+506.58%
-0.110
-52.17%
Estimates Revision
The market is revising Downward the revenue expectations for Femasys Inc. (FEMY) for FY2025, with the revenue forecasts being adjusted by -17.6% over the past three months. During the same period, the stock price has changed by -18.71%.
Revenue Estimates for FY2025
Revise Downward
-17.6%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-12.2%
In Past 3 Month
Stock Price
Go Down
-18.71%
In Past 3 Month
2 Analyst Rating
Wall Street analysts forecast FEMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FEMY is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.657
Low
3.00
Averages
5.50
High
8.00
Current: 0.657
Low
3.00
Averages
5.50
High
8.00
JonesResearch
Buy
downgrade
$10 -> $6
2025-05-13
Reason
JonesResearch
Price Target
$10 -> $6
2025-05-13
downgrade
Buy
Reason
JonesResearch lowered the firm's price target on Femasys to $6 from $10 and keeps a Buy rating on the shares. The company reported Q1 earnings with no major updates to catalysts or its cash runway, the analyst tells investors in a research note. The firm remains positive on Femasys, but cut its price target to reflect the delayed launch of FemaSeed and an increase in share count from potential financing in 2025.
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$15
2025-03-28
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$15
2025-03-28
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Maintains
$12 → $15
2025-03-19
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$12 → $15
2025-03-19
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$12
2025-03-18
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$12
2025-03-18
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$12
2025-03-13
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$12
2025-03-13
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$12
2025-02-26
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$12
2025-02-26
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Femasys Inc (FEMY.O) is -1.55, compared to its 5-year average forward P/E of -2.18. For a more detailed relative valuation and DCF analysis to assess Femasys Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-2.18
Current PE
-1.55
Overvalued PE
-0.53
Undervalued PE
-3.83
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
14.83
Current PS
0.64
Overvalued PS
33.68
Undervalued PS
-4.02
Financials
Annual
Quarterly
FY2025Q2
YoY :
+84.78%
409.27K
Total Revenue
FY2025Q2
YoY :
-14.07%
-3.85M
Operating Profit
FY2025Q2
YoY :
-2.11%
-4.59M
Net Income after Tax
FY2025Q2
YoY :
-23.81%
-0.16
EPS - Diluted
FY2025Q2
YoY :
-1.85%
-4.45M
Free Cash Flow
FY2025Q2
YoY :
+10.48%
40.27
Gross Profit Margin - %
FY2025Q2
YoY :
-32.19%
-1.08K
FCF Margin - %
FY2025Q2
YoY :
-47.02%
-1.12K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
FEMY News & Events
Events Timeline
2025-11-03 (ET)
2025-11-03
08:37:21
Femasys receives FDA clearance to proceed with the final phase of FemBloc trial.
2025-10-22 (ET)
2025-10-22
09:05:25
Femasys Launches Post-Market Surveillance Study for FemBloc
2025-10-16 (ET)
2025-10-16
14:09:42
Femasys Soars as Trump Anticipated to Broaden IVF Accessibility
Sign Up For More Events
Sign Up For More Events
News
9.0
10-24NASDAQ.COMINBX Rises 81% Following Study Results; FEMY, CING, CYH Surge in After-Hours Trading
2.0
10-03TipRanksVTI ETF Update, October 3, 2025
7.5
09-23Yahoo FinanceFemasys Collaborates with Medical Electronic Systems on FemSperm Kit Development
Sign Up For More News
People Also Watch
NRSN
Neurosense Therapeutics Ltd
1.080
USD
-3.57%
TRT
Trio-Tech International
7.190
USD
-2.57%
LVTX
LAVA Therapeutics NV
1.630
USD
+0.31%
LGVN
Longeveron Inc
0.831
USD
-0.36%
MXC
Mexco Energy Corp
9.490
USD
+3.15%
KFFB
Kentucky First Federal Bancorp
3.980
USD
-1.00%
ENLV
Enlivex Therapeutics Ltd
1.050
USD
0.00%
UTSI
UTStarcom Holdings Corp
2.370
USD
-5.20%
CODX
Co-Diagnostics Inc
0.404
USD
-12.17%
FAQ
What is Femasys Inc (FEMY) stock price today?
The current price of FEMY is 0.6571 USD — it has increased 3.14 % in the last trading day.
What is Femasys Inc (FEMY)'s business?
What is the price predicton of FEMY Stock?
What is Femasys Inc (FEMY)'s revenue for the last quarter?
What is Femasys Inc (FEMY)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Femasys Inc (FEMY)'s fundamentals?
How many employees does Femasys Inc (FEMY). have?